Immix Biopharma IMMX
NASDAQ IMMX
$8.51 -0.40 (-4.49%)
At close: Oct 21, 2026 · 4:00 PM EDT

Immix Biopharma (IMMX) Short term Debt (2020)

Updated

Immix Biopharma's Short term Debt was $4.05 million in Q4 2020.

Analysis

Immix Biopharma (IMMX) Short term Debt (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Immix Biopharma 541.74 Mn 309.64 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 4.05 Mn
API Access

Immix Biopharma Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=IMMX&period=max&api_key=YOUR_API_KEY